Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued ...

Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.

Get the live share price of Alnylam Pharmaceuticals Inc (ALNY), including intraday charts, historical performance, key ...

Arrowhead Pharmaceuticals (ARWR) is back in focus after fresh regulatory approvals for REDEMPLO in China and Canada, along ...

Viruses occupy a central place in ecology and health, influencing the dynamics of terrestrial, aquatic, and managed ...

Patients receiving concomitant PCSK9 inhibitor therapy experienced greater LDL cholesterol reductions, exceeding 50% during ...

Arrowhead Pharmaceuticals said Tuesday that its gene-silencing drug candidate nearly doubled four-month weight loss ...

RNA drugs are a new type of medicine that treat disease by influencing how cells use genetic information, rather than by ...

Shares of Arrowhead Pharmaceuticals rose after the company reported positive interim data from two Phase 1/2 trials for obesity treatments. The stock was up 17%, at $74.61, late Tuesday morning and ...

Arrowhead Pharmaceuticals today announced interim results from two Phase I/IIa clinical trials of ARO-INHBE and ARO-ALK7, the ...

Arrowhead Pharmaceuticals reported early trial data showing notable reductions in body, liver, and visceral fat from two experimental obesity drugs, with more results expected in 2026.

SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal ...